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1. Introduction
The development of drug-delivery systems (DDSs) has attracted 
significant attention over the last 40 years. This has been 
driven by the importance of improving the clinical perfor-
mances of various therapeutics and the need to develop novel 
diagnostic sensing and imaging tools. DDSs rely greatly on 
Drug-delivery systems (DDSs), in which drug encapsulation in nanoparticles 
enables targeted delivery of therapeutic agents and their release at specific 
disease sites, are important because they improve drug efficacy and help to  
decrease side effects. Although significant progress has been made in the develop-
ment of DDSs for the treatment of a wide range of diseases, new approaches 
that increase the scope and effectiveness of such systems are still needed. 
Concepts such as nanoreactors and nanofactories are therefore attracting 
much attention. Nanoreactors, which basically consist of vesicle-encapsulated 
enzymes, provide prodrug conversion to therapeutic agents rather than simple 
drug delivery. Nanofactories are an extension of this concept and combine 
the features of nanoreactors and delivery carriers. Here, the required features 
of nanofactories are discussed and an overview of current strategies for the 
design and fabrication of different types of nanoreactors, i.e., systems based 
on lipid or polymer vesicles, capsules, mesoporous silica, viral capsids, and 
hydrogels, and their respective advantages and shortcomings, is provided. In 
vivo applications of biocatalytic reactors in the treatment of cancer, glaucoma, 
neuropathic pain, and alcohol intoxication are also discussed. Finally, the pros-
pects for further progress in this important and promising field are outlined.
Therapeutic Nanofactories
© 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. This is an open access article under the terms of the Creative 
Commons Attribution License, which permits use, distribution and re-
production in any medium, provided the original work is properly cited.
nanotechnology. For example, active thera-
peutic drugs are encapsulated in nanopar-
ticles (e.g., micelles, vesicles, solid-sphere 
particles, nanogels, and viruses), and 
delivered to, and are released at, desired 
places in living bodies. This enables 
enhancement of therapeutic effects and a 
reduction in side effects. Such nanotech-
nology-based DDSs (i.e., nanomedicines) 
have been investigated for the treatment 
of many diseases. In cancer therapy, for 
instance, several nanomedicines such as 
Doxil, Abraxane, and Onivyde have been 
approved for clinical use and have signifi-
cantly improved patient survival.[1,2] Other 
novel nanomedicines have shown superior 
anticancer activity in preclinical studies.[3] 
Although these conventional nanomedi-
cines have valuable therapeutic effects, 
their effects are limited to extending 
patient survival, and patients still suffer 
from side effects. There is therefore a 
growing need for different approaches to 
the development of novel nanomedicines.
In addition to conventional DDSs, the concept of using 
enzymatic reactions to convert a prodrug to a therapeutic drug 
(known as enzymatic prodrug therapy, EPT) has been used 
for DDS development since the mid-1980s. Nishiyama et al. 
reported the use of cytosine deaminase (CD) encapsulated 
in a dialysis bag as an implantable device for local enzymatic 
prodrug conversion.[4] They reported that local implantation of 
capsules containing CD and subsequent addition of 5-fluorocy-
tosine (5-FU) effectively converted 5-FU to 5-fluorouracil, which 
led to inhibition of tumor growth.
This work showed that EPT is a powerful therapeutic tool 
and various types of EPTs have been developed to improve ther-
apeutic efficiency. For example, Bagshawe reported an enzyme 
conjugated antibody that can deliver the enzyme to a specific 
disease site where the enzyme can convert a prodrug into an 
active drug.[5] The released drug can be diffused into cells (e.g., 
cancer cells), leading to cell death. This method is known as 
antibody-directed enzyme prodrug therapy (ADEPT). Because 
of these superior therapeutic effects, several clinical trials using 
ADEPT have been performed.[6] Drug-conjugated polymers 
have also been used to construct enzyme prodrug activa-
tion systems for polymer-directed enzyme prodrug therapy 
(PDEPT).[7,8] This system consists of a drug immobilized on 
a polymer via a cleavable linker for selective inter-/intracel-
lular enzymatic reactions by specific enzymes at disease sites. 
In 2005, Gelder and co-workers reported another EPT-based 
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concept, i.e., therapeutic nanoreactors.[9,10] These consist of a 
biocatalyst (enzyme) encapsulated in polymer vesicles equipped 
with a channel protein and are designed to transform prodrugs 
into therapeutic drugs by an encapsulated enzyme. EPT has 
great potential for the treatment of a variety of diseases, and 
many excellent reviews that cover the history of, and recent pro-
gress in, EPT are available.[11–13]
In 2007, a working group including chemists, engineers, and 
medical researchers extended the concept of such therapeutic 
reactors to more elaborate biocatalytic reactors, namely nano-
factories.[14] A nanofactory is a compartment with the charac-
teristics of both a biocatalytic reactor and a delivery carrier; it 
performs specific functions at disease sites, in either intra- or 
intercellular environments. The difference between an EPT 
system and a nanofactory is that a nanofactory is designed to 
act mainly in intracellular environments rather than extracel-
lular environments. More specifically, nanofactories can trans-
port enzymes to intracellular environments, at which toxic 
materials or prodrugs are selectively permeated inside the 
nanofactories and transformed into harmless compounds or 
native drugs. Such in situ production of therapeutic drugs and 
detoxification has distinct advantages over conventional DDSs, 
namely a reduction in unwanted side effects and enhanced 
therapeutic efficacy.
The working group reported that five requirements (Figure 1) 
need to be fulfilled by such nanofactories (i.e., therapeutic bio-
catalytic reactors): 1) the presence of a structural compartment; 
2) transportation of specific molecules to and from the outer 
environment; 3) accumulation at the target site; 4) enzyme 
encapsulation, and 5) self-destruction in response to an external 
trigger. The construction of such nanofactories is therefore a 
great challenge. In recent years, however, compartments that 
fulfill several of the above requirements have been developed 
and have potential for nanofactory production.
This review aims to describe various strategies for the fab-
rication of biocatalytic reactors. The major merits of each 
strategy are highlighted and the remaining drawbacks are also 
discussed. Such biocatalytic reactors have also been used for 
the construction of artificial cells or organelles, and there are a 
large number of literature reports and excellent reviews on this 
topic,[15–20] but this is beyond the scope of this review. Finally, 
we will highlight some of the challenges in the use of biocata-
lytic reactors for in vivo medical applications.
2. Design Strategies and Functions of Biocatalytic 
Reactors
Enzymes are biocatalysts that can accelerate a wide variety 
of reactions such as decomposition of harmful compounds. 
Consequently, enzymes can be regarded as medicines.[21] 
However, externally introduced enzymes are easily denatured 
in living bodies (e.g., in the blood stream and inside cells), 
and are recognized by the immune system, leading to exclu-
sion. They therefore need to be protected from the external 
environment by placing them in structural compartments. 
The cells and organelles in living systems have biological 
membranes, which are composed of lipid bilayers. Bilayer 
membranes separate the inner aqueous phase from the outer 
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Figure 1. Requirements for therapeutic nanofactories.
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environment by compartmentalization. This provides integra-
tion of functional molecules such as enzymes and a specific 
reaction space. The compartmentalization of enzymes is a 
result of natural selection and therefore provides a rational 
approach to the performance of effective enzymatic reac-
tions. In addition to enzyme entrapment, compartments 
acting as therapeutic biocatalytic nanoreactors must fulfill the 
five requirements listed in the introduction. Much effort has 
been made to develop compartments that can act as biocata-
lytic reactors.[22] In the following section, we provide an over-
view of strategies for designing biocatalytic reactors based on 
various scaffolds (e.g., lipid and polymer vesicles, capsules, 
mesoporous silica, viral capsids, and hydrogels) and their bio-
catalytic activities in aqueous solution and intracellular envi-
ronments (Figure 2).
2.1. Lipid Vesicles
Lipid vesicles, or liposomes, which are constructed by self-
assembly of certain phospholipids, have one or more closed 
compartment(s). The compartments retain various molecules, 
including enzymes, without leakage, and have moderate sta-
bility. They are therefore suitable structural components 
for biocatalytic reactors. Although lipid vesicles are good 
candidates for reactors, as mentioned before, they have the 
drawback of low molecular permeability. Because of their low 
permeability, externally added substrates hardly permeate into 
lipid vesicle interiors, therefore the enzyme reaction cannot 
occur inside the vesicles.[23] In the following section, we will 
discuss strategies for enhancing the molecular permeability of 
lipid vesicles.
2.1.1. Temperature-Responsive Vesicles
Lipid bilayers show phase-transition temperatures (Tm). When 
a liposome solution is heated, the bilayer undergoes a transi-
tion from a gel phase to a ripple phase and then a liquid-crystal 
phase. During phase separation, the mobility and fluidity of the 
lipid molecules in the membrane can be altered. The bilayer 
membrane in the liquid-crystal phase is more permeable than 
that in the gel phase. Researchers have used this property in 
liposome-based biocatalyst reactors. For example, Kaszuba and 
Jones prepared glucose oxidase (GOD)-loaded dimyristoylphos-
phatidylcholine (DMPC; Tm = 23.6 °C) and measured the GOD 
activities at various temperatures.[24] At 10 °C, the GOD activity 
was negligible, and the activity was the highest at 20 °C. This is 
consistent with the Tm values of DMPC.
More recently, Stevens and co-workers developed electrospun 
fibers with embedded liposome-encapsulated enzymes for bio-
catalytic matrices, as shown in Figure 3.[25] They used DMPC 
and 1,2-dipalmitoyl-glycero-3-phosphocholine (DPPC) phos-
pholipids for the preparation of liposomes and encapsulated 
β-glucuronidase (β-Glu) in the vesicles, followed by processing 
into nonwoven fibers by electrospinning. The β-Glu activities 
of the liposomes embedded in the fibers were evaluated on the 
basis of conversion of fluorescein di-β-glucuronide. At 37 °C, 
the fluorescence signal derived from fluorescein was four times 
higher than that at 20 °C because of enhanced permeability of 
the substrate above the phase-transition temperature of DMPC. 
They further demonstrated the therapeutic use of this biocata-
lytic matrix by producing an antiproliferative drug (SN-38) in 
the presence of HeLa cells.
2.1.2. Reconstituted Membrane Protein Vesicles
Cells and organelles take up nutrients via membrane channel 
proteins. Inspired by these natural systems, researchers have 
used membrane channel proteins to increase the molecular 
permeability of lipid vesicles. Meier and co-workers reported 
channel membrane proteins (porin, OmpF) embedded in 
polymer-stabilized phospholipid liposomes. The embedded 
OmpF acted as a channel, and allowed permeation of low-
molecular-weight compounds (less than 400 g mol−1). This 
enabled liposome-encapsulated β-lactamase to act as a 
nanoreactor for hydrolysis of the antibiotic ampicillin inside 
the liposome.[26] Nakao and co-workers developed tandem bio-
catalytic reactors using OmpF incorporated into liposomes.[27] 
The liposomes contained GOD and catalase (CAT) in the inner 
phase, and glucose was fed through the OmpF protein from the 
outer phase. The fed glucose was successfully transformed to 
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Figure 2. Schematic diagram of five different compartments in scaffold of 
biocatalytic reactor. Lipid & polymer vesicles, left: Reproduced with per-
mission.[62] Copyright 2016, Wiley-VCH, right: Reproduced with permis-
sion.[72] Copyright 2017, Wiley-VCH. Polymer capsules, left: Reproduced 
with permission.[84] Copyright 2012, American Chemical Society, right: 
Reproduced with permission.[88] Copyright 2010, Wiley-VCH. Mesoporous 
silica particles, top: Reproduced with permission.[131] Copyright 2013, 
American Chemical Society, bottom: Reproduced with permission.[134] 
Copyright 2014, Wiley-VCH. Virus capsids, left: Reproduced with per-
mission.[137] Copyright 2007, Springer Nature, right: Reproduced with 
permission.[141] Copyright 2014, Royal Society of Chemistry. Hydrogels & 
polymer film, Reproduced with permission.[149] Copyright 2014, The Royal 
Society of Chemistry.
www.advancedsciencenews.com
1800801 (4 of 23) © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
gluconic acid and H2O2 by GOD, followed by decomposition of 
H2O2 to water and oxygen by CAT.
2.1.3. Transient Hole Formation by Detergents
The methods described in Sections 2.1.1 and 2.1.2 (tempera-
ture and reconstitution of membrane proteins) are the main 
strategies for enhancing permeability, but another technique 
has been developed. Schmidt and co-workers found that the 
addition of sodium cholate to liposomes induced the formation 
of transient holes in the bilayer membrane. The polysaccharide 
inulin, with an average molecular weight of 7 × 104 g mol−1, 
can be loaded into the liposomes via the transient holes.[28–30] 
Oberholzer et al. used this method for saccharide chain 
elongation of glycogen by the reaction of phosphorylase and its 
substrate glucose monophosphate,[31] and polyadenine forma-
tion by the reaction of polynucleotide phosphorylase and aden-
osine 5′-diphoshphate inside liposomes.[32] Sodium cholate and 
triton X-100[33] both increased the phospholipid bilayer mem-
brane permeability.
2.1.4. Organic–Inorganic Hybrid Vesicles
Another approach to the fabrication of permeable lipid vesicles 
is to use organic–inorganic hybrid vesicles, as reported by Yasu-
hara et al.[34] The lipid vesicles consisted of an organoalkoxysi-
lane lipid, i.e., N,N-dihexadecyl-N-α-{6-[(3-triethoxysilylpropyl)
dimethylammonio]hexanoyl}alaninamide} bromide, and were 
stabilized by formation of a crosslinked siloxane (Si–O–Si) 
network on the membrane surface (Figure 4). The resulting 
vesicles acted as molecular sieves and allowed permeation 
of hydrophilic molecules of molecular weights less than 
1.5 kg mol−1. Because of this semipermeability, benzoyl-
l-tyrosine-p-nitroanilide passed through the membrane and 
α-chymotripsin encapsulated inside the vesicles successfully 
hydrolyzed the substrate. The proposed permeability mecha-
nism is associated with the formation of domains with an oli-
gosiloxane surface. This leads to packing defects at the domain 
boundary, and these facilitate permeation. This semiperme-
ability and structural stability endowed by crosslinking would 
be beneficial in therapeutic biocatalytic nanoreactors.
2.2. Polymer Vesicles
Although liposomal compartments with enhanced molecular 
permeability can be used in biocatalytic nanoreactors, their 
stabilities in physiological environments are limited. Enhance-
ment of the membrane stability can therefore be of considerable 
benefit in biocatalytic reactors in vivo. In 1995, Eisenberg and 
co-workers discovered amphiphilic block copolymers, which 
are structural analogs of phospholipids, and could form spher-
ical vesicles.[35,36] Shortly afterward, Discher et al. coined the 
term polymersome for this type of vesicle.[37] The bilayers of 
polymer vesicles are much thicker than those of phospholipid 
membranes, and have the advantages of superior stability 
and toughness.[38] The membrane stability increases with 
increasing thickness (i.e., molecular weight of the polymer), 
but the permeability decreases considerably. Accordingly, sub-
stantial efforts have been made to develop functional polymer 
vesicles with improved molecular permeability. The chemical 
properties can be engineered by changing the molecular weight 
and chemical structure of the block segment, therefore a wide 
variety of biocatalytic nanoreactors based on polymer vesicles 
Adv. Sci. 2018, 5, 1800801
Figure 3. Schematic diagrams of A) preparation of electrospun poly(vinyl alcohol) (PVA) fibers with embedded β-glucuronidase-loaded liposomes and 
B) enzymatic conversion of fluorescein diglucuronide to fluorescein by PVA fibers containing β-glucuronidase-loaded liposomes at 37 °C, which is above 
the Tm of 1,2-dioleoyl-glycero-3-phosphocholine (DOPC) lipid. Reproduced with permission.[25] Copyright 2017, Wiley-VCH.
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have been reported. In the next section, some key examples are 
described.
2.2.1. Stimuli-Responsive Polymer Vesicles
A wide variety of stimuli-responsive polymer vesicles that can 
undergo physical and chemical changes such as swelling, disas-
sembly, and bond cleavage in response to a specific stimulus 
(e.g., pH, temperature, and light) have been reported.[39] These 
vesicles are mainly designed for the controlled release of a 
loaded drug at a desired place in living cells or specific tissues. 
Some stimuli-responsive vesicles are designed to enhance the 
membrane permeability in response to external stimuli. In the 
following section, we will describe the design of polymer vesi-
cles that can alter the molecular permeability by responding to 
external stimuli, and their functions as biocatalytic reactors.
pH-Responsive Polymer Vesicles: Significant acidification of tis-
sues occurs in response to irregular physiological states such 
as inflammation and cancer. Acidified cellular components 
(lysosomes) are also present in living cells. Consequently, 
polymer vesicles with permeability that can be controlled by 
pH changes can provide site-specific biocatalytic reactors. The 
first example of polymer vesicles equipped with pH-responsive 
transmembrane channels was reported by Chiu et al. in 2008.[40] 
The vesicles were produced by self-assembly of copolymers 
of acrylic acid (AAc) and 1,2-distearoylglycerol acrylate (DSA). 
The authors suggested that the DSA part of the copolymer was 
self-assembled into a bilayer and AAc formed domains in the 
membrane. These AAc domains acted as pH-responsive trans-
membrane channels. Calcein (a water-soluble fluorophore) 
passed through the membrane at pH 8.0 but permeation by 
calcein was prohibited at pH 5.0. At pH 8, the vesicles were 
permeable not only to calcein but also to high-molecular-weight 
compounds such as hemoglobin. AAc ionization increased with 
increasing pH of the vesicle suspension, and this facilitated 
disruption of hydrogen bonds. This enhanced the molecular 
permeability when the pH increased. However, the sizes of 
these vesicles are too large for systemic injection and reduction 
to the nanometer scale is needed.
Voit and co-workers reported another approach to modulate 
the permeability of polymer vesicle membranes, which involves 
the use of pH-sensitive photo-crosslinkable copolymers.[41,42] 
Their polymers consisted of biocompatible poly(ethylene glycol) 
(PEG) as a hydrophilic segment, pH-sensitive diethylaminoe-
thyl methacrylate (DEAEMA), and a photo-crosslinking unit, 
i.e., 3,4-dimethylmaleic imidobutyl methacrylate (DMIBM). 
Polymer vesicles of average size 120 nm were obtained by a 
pH switching method. Photoirradiation of the vesicle solution 
resulted in crosslinking of the DMIBM units in the mem-
brane, which led to the formation of crosslinked polymer vesi-
cles. These polymer vesicles showed pH-dependent swelling/
deswelling behavior because of the pH responsiveness of the 
poly(DEAEMA) (PDEAEMA) moiety. At high pH (pH 10), the 
DEAEMA chains are unprotonated and hydrophobic, leading to 
association, whereas they are protonated and hydrated at pH 4. 
Reversible swelling can be achieved by these pH changes. The 
vesicles were permeable in the acidic state and acted as bioreac-
tors for the oxidation of guaiacol by myoglobin (Mb). A more 
interesting property of this vesicle is that the permeability is 
enhanced by shear flow, probably because of pore formation. 
This unique feature could enable the use of therapeutic nano-
factories in blood vessels.
The same research group also reported another pH-respon-
sive polymer vesicle, which was based on PEG-b-poly(DEAEMA-
stat-2-hydroxy-4-(methacryloyloxy)benzophenone.[43,44] Du and 
co-workers also developed photo-crosslinked polymer vesicles 
that can transport bio-macromolecules (enzymes and small 
interfering RNA (siRNA)) inside the vesicle lumen on the basis 
of pH changes.[45]
Light-Responsive Polymer Vesicles: The pH-responsive systems 
described above involve a two-step procedure for fabrication of 
permeable vesicles. The first step is crosslinking for stability 
enhancement, and the second step is permeability control by 
changing the pH. Such systems are unsuitable if both stability 
and permeability are needed because these characteristics are 
incompatible. Consequently, another approach is needed. Liu 
and co-workers are at the forefront of research on this issue. 
They have developed a new strategy, which involves light-
induced traceless crosslinking of polymer vesicles, as shown 
Adv. Sci. 2018, 5, 1800801
Figure 4. A) Chemical structure of organoalkoxysilane lipid and schematic diagram of semipermeable organic–inorganic hybrid vesicle and B) mole-
cular weight–dependent release of FITC–PEGs with different molecular weights from organic–inorganic hybrid vesicles. Reproduced with permission.[34] 
Copyright 2013, The Royal Society of Chemistry.
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in Figure 5.[46] This strategy is based on amphiphilic block 
copolymers with a hydrophobic unit containing photolabile 
carbamate-caged primary amine moieties (i.e., 2-nitrobenzy-
loxycarbonylaminoethyl methacrylate). The polymers are self-
assembled into vesicles and on irradiation with UV light, the 
nitrobenzyl moieties are deprotected and primary amines are 
released. This results in the formation of inter- and intramo-
lecular amide bonds. This leads to membrane crosslinking, 
accompanied by hydrophobic to hydrophilic transitions of the 
membrane. This feature enables the fabrication of permeable 
vesicles. For example, doxorubicin, which is a hydrophilic 
molecule, can be encapsulated inside the vesicle and released 
by UV irradiation. The release rate increases with increasing 
UV irradiation time, therefore the crosslinking density can 
be controlled by the irradiation time. The authors used this 
system to fabricate biocatalytic nanoreactors with switch on/off 
properties. They chose alkaline phosphatase (ALP) as a model 
enzyme for encapsulation in the vesicles. On UV irradiation, 
the vesicles were converted to permeable vesicles, and the non-
fluorescent ALP substrate was able to pass through the mem-
brane. The resulting substrate was hydrolyzed by ALP inside 
the vesicles to yield a fluorescent product.
The vesicle permeability can be altered by light irradia-
tion, but the process is irreversible and a by-product, which 
could be cytotoxic, is produced. Shortly after this report, they 
improved the system and developed polymer vesicles with 
molecular permeability that can be reversibly switched.[47] In 
this system, photoswitchable spyropyran was incorporated 
into the hydrophobic segment of the amphiphilic polymer. On 
irradiation with light, the spyropyran was transformed into 
merocyanine, and the polymer membrane became disordered. 
This facilitated membrane permeability. When the vesicle 
solution was exposed to visible light, merocyanine was con-
verted to the original spyropyran, and the membrane became 
impermeable.
Light has several advantages over other stimuli: mild activa-
tion, precise remote spatiotemporal control, and ease of use. 
However, visible or UV light does not penetrate deep into tis-
sues because of light absorption and scattering. This hampers 
potential use of these light sources in further in vitro and in 
vivo biomedical applications. Although the use of near-infrared 
(NIR) light in the range 700–1000 nm, which is the optical 
tissue penetration window, is one solution to this issue, NIR 
light–responsive systems have not yet been reported.
Chemical-Responsive Polymer Vesicles: Another approach to 
functionalized permeability is to make use of the presence of 
specific molecules in pathological situations. van Hest and co-
workers reported the first example of polymer vesicle perme-
ability induced by chemical stimuli.[48] They formed vesicles by 
coassembly of PEG-b-poly(styrene) (PS) and PEG-b-poly(styrene 
boronic acid) (PSBA), which is a sugar-responsive polymer. 
The vesicles have holes in their membranes when fructose 
(100 × 10−3 m) was present. The PSBA units bind to fructose, 
which increases the water solubility of PSBA. This results in 
disassembly of PEG–PSBA from the vesicles, but PEG–PS 
retains its structural integrity. This results in formation of 
vesicles with holes. As expected, the holes acted as transporting 
channels for small water-soluble molecules such as carboxyflu-
orescein. The authors reported that Candida antrarctica lipase B 
(CALB) encapsulated in a polymersome nanoreactor catalyzed 
the hydrolytic reaction of 6,8-difluoro-4-methylumbelliferyl 
octanoate (DiFMU octanoate).
Adv. Sci. 2018, 5, 1800801
Figure 5. Chemical structure of photoresponsive amphiphilic block copolymer and schematic diagram of vesicles, showing phototriggered traceless 
crosslinking and vesicle membrane permeabilization. Reproduced with permission.[46] Copyright 2014, Wiley-VCH.
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Yuan and co-workers developed another type of stimulus-
responsive polymer vesicle, with permeability that can be tuned 
by using CO2-responsive polymers (Figure 6).[49] The vesicles were 
constructed by self-assembly of PEG-b-poly[(N-amidino)dodecyl 
acrylamine] (PAD). On exposure to CO2, the membrane thick-
ness increased. This change is ascribed to a change in the pro-
tonation degree of the PAD unit, which accompanies hydration 
of the hydrophobic layer. During CO2 exposure, the membrane 
swelled, allowing permeation of hydrophilic molecules such as 
polyethyleneimine (PEI). More interestingly, molecular size–
dependent permeability can be achieved by changing the CO2 
exposure time; exposure for 10 min enabled permeation of PEI 
of molecular weight 5 kg mol−1, whereas PEIs of molecular 
weights 5 and 25 kg mol−1 both passed though the membrane 
after 30 min exposure. This property was used to elegantly 
show that on exposure to CO2, vesicles with entrapped Mb were 
permeable to O2 and glutathione, leading to the formation of 
O2-carrying Mb inside the vesicles.
Although functionalization of the permeability of these 
systems is simple and they can be used as biocatalytic nano-
reactors, a high concentration of sugar is needed because of 
low affinities between boronic acids and sugar molecules.[50] 
Such high concentrations of sugar in living bodies are rarely 
observed. In addition, the CO2-responsive systems involved 
direct CO2 bubbling, which is of little relevance in biological 
environments. Another approach to the design of polymer sys-
tems that respond to biologically relevant chemical species at 
the concentrations present in biological systems is therefore 
needed. Liu and co-workers recently reported polymer vesi-
cles that can be crosslinked and permeabilized by biologi-
cally relevant levels of H2O2, on the basis of their previous 
work.[51] They prepared a PEG-based amphiphilic block 
copoly mer containing arylboronate ester–capped self-immolative 
carbamate-caged primary amine moieties. In the presence 
of H2O2, the arylboronate moieties were removed, followed 
by self-immolative decaging reactions and generation of pri-
mary amine moieties. The resulting amine moieties reacted 
inter- and intramolecularly with ester groups to form amide 
bonds. This reaction induced vesicle crosslinking, as in their 
previous report. To test the applicability of this system inside 
living cells, mitochondria, which are organelles that generate 
reactive oxygen species (ROS), targeted H2O2-reactive polymer 
vesicles were prepared. The vesicles were successfully accumu-
lated in mitochondria, followed by transformation into perme-
able vesicles, as confirmed by release of the nucleus-staining 
small molecule 4′,6-diamidino-2-phenylindole (DAPI) dye. 
They also used this property for sustained drug release, mag-
netic resonance imaging, and fluorogenic nanoreactors. This 
system is especially notable for its ability to transform perme-
able vesicles even in crowded environments (i.e., organelles). 
It is difficult to control the size of the polymer vesicle and to 
reduce it to around 100 nm. Polymer vesicles of average diam-
eter ≈500 nm were internalized into the cells; nanoparticles of 
similar sizes would immediately be entrapped by the reticu-
loendothelial system (RES) in vivo, so this system may not be 
suitable for use in systemic injections.
In addition to immobilizing stimuli-responsive units 
on polymer vesicles, there is another interesting approach 
to developing permeable vesicles. This involves incorpora-
tion of a hydrophilic molecule into a hydrophobic segment 
of an amphiphilic polymer.[52] Bruns and co-workers showed 
that poly(2-methyloxazoline)-b-poly(dimethylsiloxane)-b-(2-
methyloxazoline) with terminal acrylate groups and PEG-b-
poly(butadiene)-based polymer vesicles photoreacted with 
2-hydroxy-4′,2-methylpropiophenone (PPOH) to give polymer 
vesicles that allow low-molecular-weight molecules to penetrate 
the membrane from the external phase. This enables vesicles 
with encapsulated horse radish peroxidase (HRP) to oxidize a 
series of HRP substrates inside the vesicles. This study clearly 
proves that the photoreaction of PPOH with polymer vesicles 
is a simple method for inducing permeability, although the 
specific permeability mechanism is not clear. Such informa-
tion will be useful in permeability control and will make this 
method more versatile.
Adv. Sci. 2018, 5, 1800801
Figure 6. A) Chemical structure of CO2-responsive amphiphilic block copolymer. B) Schematic diagram of self-assembly of copolymer into polymer 
vesicles and reversible CO2-controlled breathing behavior and C) amounts of released cargo after 10 min or 2 h of CO2 bubbling and schematic diagram 
of polymer vesicles that can permeate differently sized cargos depending on CO2 levels. Reproduced with permission.[49] Copyright 2013, Wiley-VCH.
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Temperature-Responsive Polymer Vesicles: Temperature is 
another stimulus that can be used to control membrane perme-
ability. For this purpose, the well-known temperature-responsive 
polymer poly(N-isopropylacrylamide) (PNIPAM) is often intro-
duced into polymer systems to produce temperature-responsive 
assemblies. PNIPAM solutions can switch from hydrophilic to 
hydrophobic at temperatures around the lower critical solution 
temperature (LCST). Ding and co-workers used this property 
to develop temperature-induced permeable vesicles based on 
poly(2-cinnamoylethyl methacrylate) (PCEMA)-b-PNIPAM.[53] 
The hydrophobic PCEMA block was crosslinked by UV light 
irradiation, resulting in the formation of chemically crosslinked 
polymer vesicles. Vesicle-encapsulated 4-aminopyridine (used 
as a model compound) was rapidly released below its LCST 
(25 °C), and the release rate decreased above its LCST (50 °C). 
This correlated with a shift from hydrophobic to hydrophilic 
PNIPAM chains, which caused hydration and swelling of 
the membrane. This phenomenon enables substrates to pass 
through membranes and provides systems with on–off perme-
ability regulation. This concept has been used to develop other 
temperature-responsive polymer vesicle systems.[54] However, 
biocatalytic nanoreactors based on temperature-responsive vesi-
cles have not yet been obtained.
2.2.2. Polymer Vesicles with Reconstituted Membrane Proteins
As mentioned in Section 2.2, the incorporation of channel 
membrane proteins into lipid vesicles is a promising approach 
to achieving permeability. However, block copolymer mem-
branes are much thicker than lipid bilayer membranes. The 
sizes of the hydrophobic regions in membrane proteins 
are designed to fit the thicknesses of lipid membranes. The 
incorporation of membrane proteins into polymer ves-
icle membranes was therefore believed to be too difficult. 
However, Meier et al. reported incorporation of a channel 
protein (bacterial porin OmpF) into poly(2-methyloxazoline)-
b-poly(dimethylsiloxane)-b-(2-methyloxazoline) triblock 
copoly mer bilayer membranes with 
retaining channel activities.[55] The polymers 
in the membranes are highly flexible and 
can adapt to the dimensions of the channel 
proteins.[56] Since this discovery, other 
channel proteins[57] have been incorporated 
into polymer vesicle membranes to enhance 
their permeability.[58]
In 2005, Ranquin et al. showed that pol-
ymer vesicles equipped with channel mem-
brane proteins could be used to create bio-
catalytic nanoreactors.[10] These nanoreactors 
were functionalized by encapsulating the 
purine-specific nucleoside hydrolase of Tryp-
anosoma vivax (TvNH) and permeabilizing 
with channel membrane proteins (OmpF, 
Tsx). Added prodrugs such as 2-fluoroad-
enine were successfully hydrolyzed, which 
shows that the prodrugs diffused into the 
vesicle interiors through the membrane pro-
tein and were activated by TvNH.
Hunziker and co-workers further elaborated the system and 
created cell-specific integrating biocatalytic nanoreactors.[59] 
This was achieved by functionalization with the oligonu-
cleotide poly(guanylic acid) [poly(G)] of the outer surfaces of 
polymer vesicles with encapsulated trypsin. The specific inter-
actions between macrophage scavenger receptors and poly(G) 
enabled the vesicles to be internalized into only macrophages 
of a specific class; they accumulated in the endoplasmic retic-
ulum (ER) and Golgi. To evaluate the biocatalytic activity of 
the nanoreactors, all regular cellular trypsin activity was inhib-
ited by addition of specific trypsin inhibitors to the medium. 
Despite this treatment, the trypsin activity of the cells treated 
with trypsin-loaded vesicles remained intact, which shows that 
the system can act as a biocatalytic nanoreactor in specific 
organelles, i.e., artificial organelles. Palivan and co-workers 
also used this system to prepare polymer vesicles with encap-
sulated superoxide dismutase (SOD) and peroxisome to act as 
artificial peroxisomes for detoxifying superoxide radicals and 
H2O2 inside living cells (Figure 7).[60]
For the majority of reported polymer vesicles with incor-
porated channel membrane proteins, low-molecular-weight 
molecules can always pass through the channel. The enzymatic 
reaction can therefore occur everywhere when the substrates 
are present. From this perspective, on-demand enzymatic 
reactions inside vesicles are favored over traditional perme-
able nanoreactors because they enable spatiotemporal drug 
production, which can enhance therapeutic effects and reduce 
side effects. Palivan and co-workers developed biocatalytic nano-
reactors with pH-triggered enzyme activation systems based 
on poly(2-methyloxazoline)-b-poly(dimethylsiloxane)-b-poly(2-
methyloxazoline) polymer vesicles embedded with chemically 
modified channel porins.[61] They introduced Cy5 dye into the 
amino acid residues located inside the constricted zones of the 
OmpF pores via an acid-labile hydrazone linker. The chemi-
cally modified OmpF served as a “gate,” enabling pH-driven 
molecular flow through the membrane.
Although functionalization of polymer vesicles with natural 
channel proteins is a robust method for preparing permeable 
Adv. Sci. 2018, 5, 1800801
Figure 7. A) Chemical structure of amphiphilic polymer that can incorporate channel protein 
OmpF into polymer vesicle membrane. B) Schematic diagram of artificial peroxisomes that 
contain a set of antioxidant enzymes (SOD and lactoperoxidase (LPO) or CAT) in polymer 
vesicle with channel membrane proteins, and C) schematic enzymatic cascade reaction occur-
ring inside artificial peroxisomes and serving to detoxify superoxide radicals and related H2O2. 
Reproduced with permission.[60] Copyright 2013, American Chemical Society.
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vesicles, this approach requires specific amphiphilic poly-
mers capable of incorporating membrane proteins, and the 
preparation of membrane proteins is complicated and is not 
scalable. Additionally, it is difficult to control the pore size 
or pore surface properties. In addition to the use of natural 
membrane proteins as channels for small molecules, artificial 
channel molecules have also recently been used to render 
polymer vesicles permeable. An elegant example, reported by 
Battaglia and co-workers, involved the use of DNA-based nan-
ochannels.[62] The DNA nanochannel consisted of six inter-
connected DNA duplexes and had three cholesterol groups 
at its outer surface, enabling insertion into polymer vesicle 
membranes. The channel had the outer dimensions 9 nm 
× 6 nm and a lumen diameter of 2 nm, allowing diffusion of 
small molecules. The DNA nanochannel was successfully 
inserted into the membranes of polymer vesicles, which were 
based on poly[2-(methacryloyloxy)ethylphosphorylcholine]-b-
poly(diisopropylaminoethyl methacrylate) (PMPC-b-PDPA). 
They proved that a nanoreactor with encapsulated trypsin 
can transport a fluorogenic enzyme substrate into its lumen 
through the DNA nanochannel, followed by hydrolysis of the 
substrate by trypsin. A DNA-based nanochannel has some 
advantage over natural channel proteins, such as scalability and 
controllability of the pore size and physical properties of the 
pore surface (e.g., charge and hydrophilicity). With the rapid 
development of DNA nanotechnology, it is envisioned that 
DNA-based nanochannels will attract increasing attention.
2.2.3. Intrinsically Permeable Polymer Vesicles
In addition to polymer vesicles with permeability triggered by 
stimuli and channel protein insertion, intrinsically permeable 
vesicles have been reported. The first example of intrinsically 
permeable polymer vesicles was developed by Nolte and 
co-workers in 2003.[63] The polymer consisted of PS-b-poly[3-
(isocyano-l-alanylaminoethyl)thiophene] (PS–PIAT). CALB 
encapsulated in vesicles can transport its substrate (DiFMU 
octanoate) into the inner cavity, followed by substrate hydrol-
ysis. Another enzymatic oxidation reaction in nanoreactors 
based on such vesicles has also been reported.[64]
These polymer vesicles were used to achieve enzymatic 
polymerization of a series of lactones by CALB inside the vesi-
cles.[65] In a similar system, cascade enzymatic reactions were 
achieved by using GOD and HRP encapsulated in PS–PIAT 
vesicles.[66] Immediately after reporting this system, the same 
research group developed an enzyme cascade system in which 
all the enzymes were present in a single polymer vesicle.[67] 
This was achieved by anchoring enzymes to the surfaces of 
polymer vesicles, using click chemistry,[68] and encapsulating 
two enzymes inside the vesicles. Louzao and van Hest also 
developed antioxidant nanoreactors based on SOD and HRP 
encapsulated in polymer vesicles, which consisted of PS–PIAT 
and PEG–PS.[69]
Nallani et al. fabricated multicompartmentalized cell-
mimetic nanoreactors, which consisted of a combination of 
PS–PIAT vesicles as outer compartments, and poly(2-methyl-
oxazoline) (PMOXA)–poly(dimethylsiloxane) (PDMS)–PMOXA 
vesicles with inserted OmpF as inner compartments.[70] The 
PS–PIAT and PMOXA–PDMS–POMOXA vesicles contained 
GOD and HRP, respectively. On addition of glucose and 
amplex red, GOD inside the PS–PIAT produced gluconolactone 
and H2O2, followed by diffusion of H2O2 into the PMOXA–
PDMS–POMOXA vesicles. The HRP in the PMOXA–PDMS–
POMOXA vesicles then catalyzed oxidation of amplex red in 
the presence of H2O2. This clearly indicated that the multi-
component vesicles with two entrapped enzymes acted as cell-
mimetic nanoreactors.
It is worth noting that the use of PS–PIAT-based vesicles is 
not limited to simple enzymatic reactors or cell-mimetic reac-
tors. A study that focused on the applications of intracellular 
biocatalytic nanoreactors has been reported. In this study, van 
Hest and co-workers fabricated PS–PIAT vesicles functional-
ized with cell-penetrating trans-activator of transcription (TAT) 
peptide to enhance cellular uptake.[71] They showed that nano-
reactors with encapsulated HRP were internalized into HeLa 
cells via macropinocytosis and that these reactors catalyzed oxi-
dation of 3,3′,5,5′-tetramethylbenzidine inside living cells.
More recently, we developed intrinsic permeable polymer 
vesicles based on carbohydrate-b-poly(propylene glycol) 
(Figure 8).[72] The glycopolymer self-assembles in aqueous 
solution into a unilamellar vesicle (referred to as CAPsome) 
of average diameter 100–150 nm. The CAPsome can encapsulate 
proteins (e.g., β-galactosidase, chymotrypsin, and HRP) 
without sacrificing their activity. In contrast to other vesicles, 
a CAPsome has molecular weight–dependent molecular 
permeability without any chemical modification. Low-molec-
ular-weight compounds (less than 5 × 103 g mol−1) diffuse into 
the CAPsome. We also proved that the permeability was caused 
by the partition of molecules into the polymer membrane. This 
enhanced partition can be ascribed to the weakly hydrophilic 
nature of poly(propylene glycol). This property enables 
CAPsomes to act as enzyme reactors that can supply enzyme 
substrates to the inner aqueous phase. Furthermore, TAT 
peptide–functionalized β-galactosidase-loaded CAPsomes were 
effectively internalized into HeLa cells and transformed doxo-
rubicin and 5-fluorouridine prodrugs, leading to cytotoxicity. 
Moreover, the β-galactosidase-loaded CAPsomes acted as nano-
factories, which accumulated at tumor sites and transformed a 
doxorubicin-based prodrug into doxorubicin, inhibiting tumor 
growth. This therapeutic application will be described in more 
detail in Section 3.
Recently, O’Reilly and co-workers reported inherently perme-
able polymer vesicles composed of PEG-b-poly(2-hydroxypropyl 
methacrylate).[73,74] The polymer vesicles were prepared by 
polymerization-induced self-assembly in aqueous solution. 
During this process, enzymes such as HRP and GOD were 
loaded into the inner layer of the vesicle. Although the thick-
ness of the membrane is ≈25 nm, which is larger than those 
of other vesicle membranes, enzyme substrates can permeate 
through the membrane, allowing enzyme-loaded vesicles to act 
as enzyme reactors.
2.3. Polymer Capsules
In addition to lipid and polymer vesicles, polymer capsules 
have also been used as compartments for biocatalytic reactors. 
Adv. Sci. 2018, 5, 1800801
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Polymer capsules are generally made of hydrophilic polymers 
and have semipermeable shells. Several approaches have been 
devised for the fabrication of polymer capsules. In the following 
section, we describe three key types of polymer capsule: layer-
by-layer (LbL)-assembled capsules, polyion complex vesicles, 
and enzyme nanocapsules. A number of excellent reviews 
of the fabrication and application of LbL capsules, and their 
therapeutic cargos, have been published,[75–78] therefore we will 
discuss only the key features of LbL capsules and their use in 
biocatalytic nanoreactors.
2.3.1. Layer-by-Layer-Assembled Capsules
Among various approaches for capsule fabrication, one of the 
most reported methods is LbL assembly. This approach was 
first used by Caruso et al. in 1998.[79] Their method relies on 
stepwise adsorption of polyelectrolytes onto a sacrificial tem-
plate, followed by decomposition of the template. The chem-
ical and physical properties of such LbL capsules can be easily 
controlled.[80,81] For example, the capsule size can be tuned in 
the range from nanometers to micrometers by changing the 
size of the sacrificial template. Their surface charges, shell 
thicknesses, and shapes can also be modulated. This method 
for LbL capsule fabrication is not limited to electrostatic 
interactions. Hydrogen bonding,[82,83] covalent interactions,[84] 
and, more recently, chelating interactions[85,86] have also been 
used to fabricate LbL capsules.
The most important feature of LbL capsules is their inherent 
semipermeability.[87] The capsule shell allows the passage not 
only of low-molecular-weight compounds such as dyes and 
ions, but also of high-molecular-weight compounds, including 
polysaccharides and proteins.[88] More interestingly, this 
permeability depends on the shell thickness, porosity, and 
components. This indicates that the permeability can be tuned 
on the basis of these factors. For example, the permeability of 
poly(styrene sulfonate) (PSS)/poly(allylamine) (PAH) capsules 
by fluorescein decreased with increasing shell thickness.[89] 
Moreover, an increase in the ionic strength enhanced the per-
meability by weakening the electrostatic interactions between 
polyelectrolytes in the shell.[87]
Because of their hollow structures and the semipermeability, 
and easy control of their chemical and physical properties, LbL 
capsules have been used as biocatalytic nanoreactors. Enzyme-
loaded LbL capsules are produced by three main approaches: 
1) electrostatic deposition of the enzyme (enzyme incorporation), 
2) enzyme preloading within a template, and 3) postloading of 
the enzyme inside the LbL capsules.
The first strategy is based on incorporation of enzymes into 
electrostatically assembled shells.[76] Enzymes are essentially 
polyelectrolytes and their charge can be changed by changing 
the pH, therefore they can be incorporated into LbL capsules 
as cationic or anionic components. For example, Möhwald and 
co-workers reported α-chymotrypsin-loaded LbL capsules.[90] 
They prepared LbL capsules by stepwise absorption of PSS 
and PAH onto a melamine formaldehyde (MF) core, followed 
Adv. Sci. 2018, 5, 1800801
Figure 8. A) Chemical structure of amphiphilic maltooligosaccharide-b-poly(propylene glycol) (PPG) with schematic diagram of self-assembly of 
polymers to form permeable polymer vesicles and B) schematic diagram of coassembly of maltopentaose-containing PPG and TAT-modified PPG, and 
hydrolysis of doxorubicin prodrug by β-galactosidase-loaded TAT–CAPsomes in living cells. Reproduced with permission.[72] Copyright 2017, Wiley-VCH.
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by degradation of the MF core with an acidic solution. The 
resulting LbL capsules retained negatively charged PSS/MF 
complexes on the capsule walls and/or inside the capsules, even 
after treatment. Addition of α-chymotrypsin at an acidic pH led 
to successful entrapment of α-chymotrypsin in the capsules. 
This is ascribed to electrostatic deposition of α-chymotrypsin on 
the negatively charged PSS/MF complexes inside the capsules. 
Because of the superior permeability of the LbL membrane, the 
α-chymotrypsin-loaded capsule can act as a nanoreactor for the 
oxidation of 2,2′-azino-bis(3-ethyl benzothiazoline-6-sulphonic 
acid)  (ABTS) by H2O2. Importantly, ≈90% of the original cat-
alytic activity of the loaded α-chymotrypsin was retained even 
after incubation for 3 h at 47 °C. The same research group 
used the same method to develop HRP-loaded LbL capsules.[91] 
Although this method is applicable to a wide variety of enzymes, 
it has the drawback of decreased enzymatic activity because of 
electrostatic interactions with the shell components.
The second strategy relies on physical absorption onto tem-
plates such as mesoporous silica and CaCO3. These templates 
have porous structures, therefore enzymes can be adsorbed 
in the pores. For example, mesoporous silica–templated LbL 
capsules can be loaded with a wide variety of enzymes, including 
CAT and lysozyme.[92,93] These mesoporous silica–templated 
LbL capsules have one drawback for use as biocatalytic reac-
tors, i.e., the difficulty of decomposing mesoporous silica. The 
mesoporous silica template is generally decomposed by treat-
ment with hydrofluoric acid, which might denature the enzyme. 
In contrast, CaCO3 can easily be decomposed by treatment with 
ethylenediaminetetraacetic acid (EDTA).[94] Wu and co-workers 
prepared CAT-loaded LbL capsules by using a CaCO3 sacrificial 
template.[95] The CAT-loaded CaCO3 template was prepared by 
mixing CaCl2 and Na2CO3 in the presence of CAT. LbL coating 
with PSS and protamine of the CAT-loaded CaCO3 was then 
performed, followed by silica layer coating to enhance stability. 
Finally, the CaCO3 template was removed by dissolution with 
EDTA to yield CAT-loaded LbL capsules. When 
H2O2 was added to the capsule solution, H2O2 
decomposition was observed, indicating that 
the CAT-loaded capsule acted as a biocata-
lytic microreactor. Konrad and co-workers 
used a similar method to prepare asparginase 
(ASNase)-loaded LbL capsules.[96] In this case, 
dextran sulfate and poly-l-arginine were used 
as polyelectrolytes. They also showed that 
the ASNase-loaded capsules retained their 
enzymatic activity and inhibited growth of 
leukemic cells by depletion of l-asparginase 
in the medium. The limitation of CaCO3 tem-
plates is the difficulty in controlling its size, 
which is generally several micrometers.
The third strategy for enzyme encapsula-
tion is based on the capsule permeability. 
In this approach, enzymes are loaded into 
already formed capsules by altering the shell 
permeability. This can be achieved by stim-
uli-responsive LbL capsules that can switch 
their permeability from open to closed states. 
Capsules with permeabilities that can be 
reversibly switched in response to pH,[84,97] 
temperature,[98] and ionic strength[98] have been developed. As 
well as external stimuli, changes in solvent polarity can be used 
to switch the capsule permeability.[99,100] PSS/PAH-based cap-
sules were poured into a water/ethanol mixed solvent to form 
pores in the capsule wall, allowing diffusion of an enzyme 
(uricase) into the capsules. Subsequently, their permeability 
was decreased by changing the solvent to water. This enabled 
encapsulation of uricase inside the capsules. These strategies 
are applicable to encapsulation not only of enzymes but also of 
small molecules and other biomolecules. However, they suffer 
from low encapsulation efficiency.
In addition to the above three approaches, another interesting 
approach for loading enzymes into LbL capsules is the use of 
lipid vesicles. Caruso and co-workers used the enzyme-encap-
sulating ability of lipid vesicles to prepare LbL capsules with 
embedded enzyme-loaded lipid vesicles, i.e., capsosomes.[101] 
The semipermeable polymer shell and the enhanced perme-
ability of the lipid membrane at the phase-transition tempera-
ture enabled enzyme-loaded capsosomes to act as biocatalytic 
reactors for the hydrolysis of nitrocefin by β-lactamase[102–104] 
and for the reduction of glutathione disulfide by glutathione 
reductase.[105] The use of enzyme-loaded capsosomes has 
recently been extended to extra- and intracellular biocatalytic 
reactors. Städler and co-workers used phenylalanine ammonia 
lyase (PAL)-loaded capsosomes as extracellular microreactors 
for the conversion of phenylalanine to trans-cinnamic acid in 
the presence of human intestinal epithelial HT-29 cells, as a 
potential oral treatment for phenylketonuria (Figure 9).[106] 
Intracellular biocatalytic reactors have also been reported by 
the same research group. They developed tripeptide Arg-Gly-
Asp (RGD) peptide–coated CAT-loaded capsosomes to produce 
H2O2, which led to reduced cell viability.[19] More recently, they 
used CAT-loaded capsosomes as microreactors for detoxifica-
tion of a planar HepG2 cell culture.[107,108] Hosta-Rigau and 
co-workers further elaborated these systems and created dual 
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Figure 9. Schematic diagram of preparation and function of enzyme-loaded microreactor. 
i) Layer-by-layer assembly of poly(l-lysine) (PLL)/poly(methacrylic acid)-co-(cholesteryl meth-
acrylate) (PMAc) polymer, using silica particle template; ii) deposition of phenylalanine 
ammonia lyase-loaded liposomes, iii) surface capping by layer-by-layerassembly of PMAc layer 
and poly(dopamine) (PDA), and iv) removal of core template, and v) enzymatic conversion of 
phenylalanine (Phe) to nontoxic trans-cinnamic acid (t-ca) by phenylalanine ammonia lyase 
(PAL)-loaded microreactors above Tm of liposomes. Reproduced with permission.[106] Copyright 
2017, Wiley-VCH.
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enzyme–loaded capsosomes for conducting cascade enzymatic 
reactions in living cells.[109,110] Recently, an example of a micro-
reactor that uses two different enzymatic pathways has been 
developed by Städler and co-workers.[111] They encapsulated five 
different enzymes into capsosomes and showed that cyclical 
enzymatic reactions were achieved with a combination of glu-
tamate dehydrogenase and glutathione reductase for reduc-
tion of nicotinamide adenine dinucleotide phosphate (NADP+) 
and oxidation of nicotinamide adenine dinucleoide phosphate 
hydrogen (NADPH), and cascade reactions were achieved with 
β-galactosidase, glucose oxidase, and catalase, with lactose as a 
substrate. This mimics the biocatalytic ability of cells.
Although these studies clearly show that LbL-based capsules 
are promising candidates for biocatalytic reactors, only a few 
examples of in vitro biocatalytic reactors have been reported 
as described above.[96,106–110] This might be because of stability 
issues with the capsules, which degrade under physiological 
conditions. New ideas are therefore needed for improving 
the stability without decreasing the semipermeability of LbL 
capsules.
2.3.2. Polyion Complex Vesicles
Another elegant example of permeable polymeric compart-
ments was reported by Kishimura and co-workers.[112,113] They 
used polyion complexes of PEG–poly(α,β-aspartic acid) and 
PEG–poly([2-aminoalkyl-α,β-aspartamide] to produce polymer 
vesicles, referred to as PICsomes. These were easily prepared 
by simply mixing the polymers in aqueous solution, and 
they have semi-permeable polyion complex membranes. The 
permeability of PIC membranes is molecular-weight dependent 
and allows permeation of up to 70 kDa fluorescein isothiocy-
anate (FITC)–dextran. Nanoreactors based on Mb encapsulated 
in PICsomes can therefore be produced.[114] The encapsulated 
Mb is readily reduced to deoxyMb by permeated S2O42− from 
the outer vesicular environment and the oxidized and reduced 
states of Mb can be reversibly controlled by alternating bubbling 
of O2 and Ar gas into the nanoreactor solution. Another enzy-
matic nanoreactor system, which is based on β-galactosidase 
encapsulated in PICsomes, was also reported.[115]
The membrane permeability can be tuned by changing the 
pH[116] and crosslinking of the membrane by formation of 
amide bonds between amine and carboxyl groups of cationic 
and anionic polymers, respectively.[117,118] The resulting 
crosslinked PICsomes have improved stability under physi-
ological salt conditions and retain their size and distribution 
in a solution containing 150 × 10−3 m NaCl. In addition to this 
solution stability, the PEG surface of the PICsome enables 
long-term blood circulation in vivo.[119] It is worth noting that 
selective normal and tumor tissue accumulations were achieved 
by tuning the PICsome size. PICsomes of average diameter 
greater than 150 nm showed negligible tumor accumulation 
and significant spleen accumulation, whereas PICsomes of size 
less than 150 nm showed increased tumor accumulation and 
decreased spleen accumulation.
These PICsome characteristics were used to develop in vivo 
nanoreactors (Figure 10). For example, PICsomes with encapsu-
lated β-galactosidase were used for conversion of a fluorogenic 
substrate (HMDER-β-galactosidase).[120] β-Galactosidase encap-
sulated in PICsomes was systemically injected into CT-26 
tumor-bearing mice and was successfully accumulated in the 
tumor region. Its enzymatic activity was retained even 4 days 
after administration, confirmed by detection of fluorescence 
derived from hydroxymethyl diethylrhodol (HMDER) by in 
vivo imaging system (IVIS) and intravital real-time confocal 
microscopy. More recently, a system with ASNase encapsu-
lated in PICsomes was developed.[121] Because some leukemic 
cells are deficient in asparagine synthetase, the removal of 
asparagine has an antiproliferative effect on leukemic cells. A 
system capable of removing l-aspargine in the bloodstream 
was therefore developed. ASNase encapsulated in PICsomes 
retained its enzymatic activity and achieved enzymatic hydrol-
ysis of aspargine after systemic injection into mice, because of 
long-term circulation in the blood.
2.3.3. Enzyme Nanocapsules
The strategies for enzyme encapsulation described above are 
generally based on entrapment of enzymes in already formed 
compartments such as vesicles. Although this approach can be 
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Figure 10. A) Chemical structures of polymers that form PICsomes and preparation of enzyme@PICsomes via preformed PICsomes, and transmis-
sion electron microscopy image of β-galactosidase@PICsomes, and B) real-time observation of enzymatic reaction in C26 tumor tissue by intravital 
real-time confocal laser scanning microscopy. Reproduced with permission.[120] Copyright 2016, Wiley-VCH.
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used for facile preparation of enzyme-loaded compartments, it 
suffers from low encapsulation efficiency. This problem, which 
is related to passive encapsulation of enzymes during compart-
ment formation, was solved by Lu and co-workers.[122] Enhanced 
encapsulation efficiency was achieved by polymer shell forma-
tion on the enzyme surface. Such enzyme-templated nanocap-
sules were prepared by introduction of acrylate groups into 
enzymes, followed by radical polymerization of the surface of 
the acrylated enzymes in the presence of 2-dimethylaminoethyl 
methacrylate, acrylamide, and N,N′-methylene bisacrylamide. 
The surface charge on the capsules can be adjusted by varying 
the ratio of the cationic and neutral monomers. Degradability 
can also be incorporated by introducing glycerol dimethacrylate. 
This is a facile procedure, and the authors showed that a wide 
variety of enzymes, including enhanced green fluorescent pro-
tein, HRP, bovine serum albumin (BSA), SOD, and caspase-3 
could be used as enzyme templates. Enzyme nanocapsules were 
effectively internalized into cells and escaped from endosomes, 
possibly because of the proton sponge effect. Furthermore, the 
enzyme nanocapsules retained their enzymatic activity inside 
living cells and even in the tissues of capsule-injected mice. The 
authors have elaborated this system to develop reduction-[123] 
and enzyme-responsive[124] enzyme nanocapsules and have 
used them for organophosphate removal.[125] They also showed 
the utility of this system as a therapeutic biocatalytic reactor for 
alcohol intoxication.[126] This will be described in more detail in 
Section 3.
2.4. Mesoporous Silica Particles
Mesoporous silica particles (MSPs) provide a solid frame-
work with a porous structure. MSPs are generally prepared by 
templating methods, using surfactants and degradable solid 
materials. They can be tailored to give various structures and 
morphologies by controlling the reaction conditions such as 
temperature, pH, template, and silica source.[127] MSPs have 
pores of diameter 2–50 nm, which are suitable for enzyme 
entrapment and substrate permeation.[128,129] MSPs are there-
fore attractive materials for biocatalytic reactor compartments. 
Several studies have focused on the development of MSP-based 
biocatalytic nanoreactors, which can encapsulate or immobilize 
enzymes and convert enzyme substrates.
Trewyn and co-workers reported Au nanoparticle–capped 
MSPs for intracellular delivery of an enzyme and a sub-
strate.[130] They used channel-like mesoporous nanoparticles 
as a container for luciferin and luciferase. Luciferin was loaded 
into the pores and was confined by capping disulfide-linked Au 
nanoparticles, and luciferase was electrostatically adsorbed on 
the MSP surfaces. These MSPs with a coencapsulated enzyme 
and substrate were successfully internalized into living cells, 
as confirmed by confocal laser scanning microscopy and the 
codelivered luciferase was converted to luminescent oxyluciferin 
in vitro. The enzyme-loaded MSPs were internalized into living 
cells, but the uptake efficiency was relatively low. To tackle this 
problem, Mou and co-workers fabricated TAT peptide–func-
tionalized MSPs for enhanced intracellular delivery of enzymes 
(Figure 11).[131] Their strategy relies on functionalization of 
Ni–nitrilotriacetic acid (NTA) on mesoporous silica particles, 
followed by immobilization of a histidine-tagged TAT–SOD 
hybrid protein. As expected, the delivery efficiency of SOD–
TAT-functionalized MSPs was much better than that of control 
MSPs. When HeLa cells were exposed to a lipopolysaccharide, 
i.e., a ROS inducer, the cell viability increased and the activation 
of cleaved caspase-9 and p21 proteins decreased, suggesting 
that SOD–TAT-functionalized MSPs reduced ROS concentra-
tions in vitro. In the follow up work, an additional enzyme, glu-
tathione peroxidase, was used to enhance ROS scavenging.[132] 
Although these studies clearly show that silica nanoparticles 
are promising tools for delivering enzymes into living cells, the 
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Figure 11. A) Schematic diagram of preparation of Ni–NTA-modified mesoporous silica nanoparticles (FMSNs) with surface functionalization by 
histidine-tagged TAT–SOD protein, B) refolding of denatured SOD on FMSNs after cell internalization, and C) viabilities of HeLa cells treated with 
lipopolysaccharide, a ROS inducer, in the presence of FMSN–TAT–SOD or FMSNs. Reproduced with permission.[131] Copyright 2013, American 
Chemical Society.
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enzymes are immobilized on the MSP surfaces. They are there-
fore not protected from proteolytic degradation by endogenous 
enzymes, and this could cause immunogenicity. Protection of 
enzymes is important because it permits sustained enzymatic 
reactions and therefore increases the therapeutic efficiency. 
To this end, silica hollow nanoparticles are also used for the 
compartments of biocatalytic nanoreactors. For example, the 
same research group encapsulated HRP in silica hollow parti-
cles by a water-in-oil microemulsion templating approach.[133] 
Because template removal was unnecessary and mild washing 
conditions were used, the encapsulated HRP retained high 
enzymatic activity inside the MSPs. MSP-encapsulated HRP 
was used as an intracellular nanoreactor in a prodrug–enzyme 
system to convert nontoxic indole-3-acetic acid to toxic free 
radicals. A similar strategy was used for intracellular detoxifi-
cation of ROS by CAT and SOD coencapsulated in MSPs.[134] 
In this study, PEI-modified CAT and SOD were encapsulated 
inside the hollow silica nanospheres (HSNs). In the pres-
ence of paraquat, which is a ROS inducer, enzymes encapsu-
lated in MSPs decreased the number of dead cells by 60% by 
active removal of ROS. Many MSP-based biocatalytic nanoreac-
tors have been developed in the past few years. Various struc-
tures, including nanochannel and hollow particles, have been 
designed and fabricated. These studies clearly show the utility 
of MSPs as compartments in biocatalytic reactors, but their bio-
compatibility and degradability in vitro, and especially in vivo, 
are unclear. Accordingly, future research should include evalua-
tion of the safety of MSPs in vivo.
2.5. Viral Capsids
Viruses have 3D cages, called capsids, with an internal cavity 
that can hold genetic materials such as RNA and DNA. Viral 
capsids provide robust and highly monodispersed compart-
ments with a wide variety of shapes and sizes ranging from 
several nanometers to micrometers. Moreover, they can encap-
sulate a broad spectrum of compounds, including DNA, RNA, 
inorganic materials, and proteins. Viral capsids have therefore 
attracted interest for use in the preparation of nanoreactors.[135] 
In 2007, van Hest and co-workers reported the first viral capsid–
based biocatalytic nanoreactor.[136] This was achieved by the 
self-assembly of potato virus X capsids with anchored CALB. 
Since then, many examples of viral capsid–based biocatalytic 
nanoreactors have been reported. For example, Cornelissen and 
co-workers encapsulated HRP in capsids derived from cowpea 
chlorotic battle virus.[137] The capsids have pores of size a few 
nanometers, therefore the fluorogenic substrate dihydrorhoda-
mine 6G diffused inside the capsids, and hydrolysis by HRP 
produced a fluorescent molecule. More interestingly, the pore 
size increased with increasing solution pH to 7. This enables 
enhancement of the capsid permeability. Douglas and co-workers 
used a viral system derived from Salmonella typhimurium  
bacteriophage P22, which was assembled from 420 copies of the 
coat protein into a capsid with the assistance of 100–330 copies 
of a scaffold protein.[138] They loaded proteins (e.g., enhanced 
green fluorescent protein (EGFP), mCherry) into the capsids 
by a genetically based system, which relied on fusion of cargo 
proteins with P22 proteins.[139] They used this strategy to pre-
pare alcohol dehydrogenase encapsulated in P22 capsids for 
3-hydroxy-2-butanone (acetoin) reduction[140] (Figure 12), and 
nicotinamide adenine dinucleotide (NADH) oxidase encapsu-
lated in P22 capsids to produce H2O2 for bacterial growth inhi-
bition.[141] Recently, Vazquez-Duhalt and co-workers reported 
prodrug transformation by a biocatalytic virus inside living 
cells.[142] They also used a genetically fused system to produce 
a fusion protein containing cytochrome P450 (CyP) and a viral 
scaffold protein from bacteriophage P22. These proteins were 
successfully coassembled in enzyme-encapsulating virus-like 
compartments. These compartments were further functionalized 
with PEG–folate to give cell specificity. The folate functionality 
enabled the CyP-loaded capsids to convert 7-benzyloxy-4-trifluo-
romethylcoumarin to fluorescent 7-hydroxy-4-trifluoromethyl-
coumarin in HeLa and MCF-7 cells. Moreover, activation of a 
tamoxifen prodrug in living cells induced significant cytotoxicity.
Although viruses and their capsids have been widely used 
in nanomedicine because of their good transporting abili-
ties,[143] monodispersed size and shape, and encapsulation 
abilities, their use is hindered by potential safety issues such 
as pathogenicity and immunogenicity. These issues need to be 
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Figure 12. Schematic diagram of in vivo recombinant expression and encapsulation of alcohol dehydrogenase fusion inside assembled P22 capsid and 
reaction catalyzed by encapsulated enzyme. Reproduced with permission.[140] Copyright 2012, American Chemical Society.
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addressed in future studies to enable expansion of the use of 
viruses and their capsids.
2.6. Hydrogels and Polymer Films
Hydrogels, which are 3D networks of crosslinked polymer 
chains, have been widely investigated as promising scaffolds in 
regenerative medicine because of their high biocompatibility, 
similarities to the native extracellular matrix, and their abilities to 
encapsulate a wide variety of molecules, including peptides and 
proteins.[144,145] Low-molecular-weight compounds can penetrate 
inside a hydrogel because of the network structure, therefore 
hydrogels can entrap enzymes and are ideal for use as biocata-
lytic reactor scaffolds. The advantage of such hydrogel-based 
biocatalytic nanoreactors over typical particle-based reactors is 
that the reactors can be physically placed on a desired site such 
as tumor tissue. Particle-based biocatalytic reactors are generally 
directed to the disease site by systemic injection. This method 
is successful and can be adapted to deliver reactors to metasta-
sized tumor tissues, but only a few nanoreactors can reach the 
desired site. This decreases their therapeutic efficacy. In con-
trast, hydrogels are implantable materials that can deliver large 
amounts of enzymes locally, which enhances the therapeutic 
effect. In a seminal study, Mendes and Zelikin developed 
biocatalytic hydrogels based on poly(vinyl alcohol) (PVA) with 
embedded β-Glu for substrate-mediated DDSs (Figure 13).[146] 
They showed that hydrogels with entrapped β-Glu could convert 
three different anticancer prodrugs to cytotoxic drugs in HepG2 
cell culture media, leading to an antiproliferative effect. They 
also reported that the biocatalytic hydrogels transformed two 
different prodrugs. They used this to achieve two different anti-
inflammatory and antiproliferative effects at a desired time by 
sequential addition of curcumin–Glu and dexamethasone–Glu 
to a cell culture medium containing the biocatalytic hydrogel. 
Moreover, simultaneous coadministration of curcumin–Glu and 
SN-38–Glu enhanced their therapeutic effects. Recently, Zelikin 
and co-workers developed EPT-based systems consisting of 
two enzymes encapsulated in calcium alginate hydrogel beads 
for drug elution.[147] Alginate hydrogel beads equipped with 
β-galactosidase and β-glucuronidase were successfully used to 
synthesize both NO and an anticancer drug (SN-38), and there-
fore gave vasodilation and antiproliferation.
Hydrogels are a superior platform for embedding not only 
synthetic vesicles (liposomes) but also naturally occurring 
vesicles, i.e., extracellular vesicles (EVs) or exosomes. Stevens 
and co-workers recently reported that EVs with encapsulated 
β-glucuronidase were successfully embedded in a PVA-based 
hydrogel without sacrificing the enzymatic activity and showed 
that the EV–hydrogel hybrid produced anti-inflammatory drugs 
(curcumin) upon addition of curcumin-β-d-glucuronide.[148] 
Exosomes are involved in numerous physiological functions, 
therefore this exosome-localizing technique is a promising 
approach for exosome-based therapeutics.
At around the same time, the same research group showed 
that this strategy could be applied to polymer films pro-
duced by LbL assembly.[149,150] The biocatalytic films were 
prepared by sequential deposition of five poly(l-lysine) 
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Figure 13. A) Schematic diagram of structure of enzyme-functionalized physical hydrogels based on poly(vinyl alcohol) and differential interference 
contrast image of hydrogels and B) chemical structures of glucuronide-modified prodrug and native drug, and viabilities of hepatocyte cells cultured 
in presence of prodrugs and β-Glu-loaded hydrogels. Reproduced with permission.[146] Copyright 2014, Wiley-VCH.
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(PLL)/poly(methacrylic acid) (PMA) layers, followed by incuba-
tion of β-Glu and subsequent adsorption of another four PLL/
PMA layers. The biocatalytic activity of the film was evaluated 
on the basis of activation of SN-38–Glu in a HepG2 cell cul-
ture medium. The cell viability decreased to 80% when the cells 
were cultured on the biocatalytic film in the presence of SN-38–
Glu, indicating that the prodrug was successfully converted to 
an anticancer drug. The biocatalytic film was able to transform 
the prodrug under flow conditions. This enabled site-specific 
prodrug activation with cells cultured in sequentially connected 
flow chambers. They have recently taken biocatalytic films to 
the next level by using surface coating of metallic wires in com-
bination with their film-based EPT technique.[151] Nitric oxide 
(NO) regulates a wide variety of physiological activities such as 
inflammation, vasodilation, and antiproliferation. Although NO 
has potential as a therapeutic agent, its lifetime is very short 
(≈1 s) in human tissues and biological environment. It is there-
fore necessary to generate NO near the disease site. They there-
fore coated metal wires with biocatalytic films with embedded 
β-galactosidase. This enables delivery of the film at target sites 
through blood vessels. Such biocatalytic metal wires enabled 
localized enzymatic transformation of β-gal–diazeniumdiolate 
(NONOate) to produce NO molecules. They also achieved ex 
vivo contraction of rat artery with their biocatalytic wires.
3. In Vivo Therapeutic Biocatalytic Nanoreactors
As discussed in Section 2, there are a large number of reports 
of the development of biocatalytic nanoreactors based on lipid 
and polymer vesicles, capsules, mesoporous silica, viral capsids, 
and hydrogels. However, only a few studies of biocatalytic 
reactors for in vivo therapeutic applications have been reported. 
In the following sections, recent advances in the development 
of biocatalytic reactor–based therapies for cancer, glaucoma, 
neuropathic pain, and alcohol intoxication will be discussed.
3.1. Cancer
Cancer chemotherapies based on biocatalytic nanoreactors offer 
advantages over conventional DDSs. Biocatalytic nanoreactors 
can transform prodrugs into the original drugs in situ, which 
can maximize the therapeutic efficacy and minimize side effects.
For example, we recently reported an enzyme prodrug activation 
system for cancer therapy, which is based on β-galactosidase-
loaded polymer vesicles with inherent permeable membranes, as 
described in Section 2.2.3.[72] The polymer vesicles (CAPsomes) 
showed molecular weight–dependent permeability, enabling 
enzyme encapsulation and permeation of low-molecular-weight 
substrates. For therapeutic purposes, we used a combina-
tion of β-galactoside-modified doxorubicin as a prodrug and 
β-galactosidase-loaded CAPsomes as a biocatalytic nanoreactor. 
The prodrug activation efficacy of this system was confirmed in 
vitro with various cancer cell lines, including HeLa, CMS5a, and 
CT26, and in vivo with a CT26-bearing mouse model, in which 
tumor inhibition was confirmed by a significant reduction in 
tumor volume. More importantly, no significant systemic toxic 
effects (i.e., weight loss, acute organ toxicities) were observed.
Although our system significantly inhibited tumor growth, 
the inhibition efficacy was relatively low. The main reason could 
be different biodistributions of the prodrug and nanoreactors. 
Additionally, it has been reported that for cancer monotherapy, 
it is difficult to eliminate the whole tumor and to prevent cancer 
metastasis.[152] To overcome this drawback of monotherapy, 
combined therapies, which involve combinations of two or 
more therapies, have been developed. The use of biocatalytic 
reactors for combined cancer therapy has been reported. For 
example, Ge and co-workers developed prodrug-based polymer 
vesicles loaded with GOD, which can deliver a combination of 
chemotherapy and oxidation therapy for cancer (Figure 14).[153] 
Their polymer was PEG-b-poly[(2-methacryloyloxy)ethyl-
camptothecin oxalate]-co-poly[2-(piperidin-1-yl)ethyl meth-
acrylate) [PEG-b-poly(CPTMA-co-PEMA)]. Poly(PEMA) serves 
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Figure 14. A) Chemical structure of amphiphilic polymer containing camptothecin and pH-responsive segments, B) schematic diagram of prepara-
tion of GOD encapsulated in polymer vesicles, C) molecular mechanism of release of H2O2 and camptothecin, and D) tumor growth profiles of 
A549 tumor-bearing mice treated with PBS, free camptothecin, polymer vesicles, and GOD-loaded polymer vesicles. Reproduced with permission.[153] 
Copyright 2017, American Chemical Society.
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as a pH-responsive unit and can switch from hydrophobic to 
hydrophilic with pH changing from 7.4 to 6.8. This change 
enables permeation of low-molecular-weight compounds. The 
poly(CPTMA) segment was designed to release camptothecin, 
which is an anticancer drug, on treatment with H2O2. Polymer 
vesicles with encapsulated GOD accumulated at the tumor 
site, because of the enhanced permeation and retention (EPR) 
effect, and produced H2O2 from glucose by the enzymatic 
reaction with GOD in situ. The resulting H2O2 hydrolyzed 
the linker between the polymer and camptothecin, leading to 
camptothecin release. The produced H2O2 and camptothecin at 
the tumor site both significantly inhibited tumor growth. Fur-
thermore, H2O2 production involves consumption of glucose, 
which is a major nutrient for cancer, and therefore induces star-
vation. This could also enhance the antitumor effect. At almost 
the same time, the same researchers developed another type of 
biocatalytic nanoreactor for combined cancer therapy.[154] They 
replaced the poly(CPTMA) segment in the PEG-b-poly(CPTMA-
co-PEMA) block copolymer with a poly(phenyl boronic acid 
ester) [poly(PBEM)] segment. The poly(PBEM) segment was 
degraded by exposure to H2O2, accompanied by release of qui-
none methide (QM). QM can deplete intracellular glutathione, 
and this weakens the antioxidative properties of cancer cells. 
After intravenous injection of GOD-loaded polymer vesicles, 
the H2O2 levels in the tumor tissue were considerably higher, 
and the glutathione levels were significantly lower, than those 
after treatment with phosphate buffered saline (PBS). This con-
firmed the ability of the reactor to produce H2O2 and quinone 
methide. This synergistic effect resulted in thorough suppres-
sion of A549 tumor growth.
The scaffold for a cancer therapeutic reactor is not limited to 
polymer vesicles. For example, Shi and co-workers used den-
dritic mesoporous nanoparticles (DMSNs) as a reactor scaf-
fold.[155] Because of their highly porous nature, DMSNs can be 
loaded with both GOD and Fe3O4. The therapeutic mechanism 
of such catalytic nanoreactors is based on starvation, i.e., deple-
tion of nutrients, and generation of hydroxyl radicals. GOD oxi-
dizes glucose in the tumor region to gluconic acid and H2O2. 
The resulting H2O2 reacts with Fe3O4 at acidic pH via Fenton-
like reactions to produce toxic hydroxyl radicals. This enables 
therapeutic nanoreactors to act in a tumor-specific manner 
because of the acidic environment around the tumor. Systemic 
injection of DMSNs loaded with GOD and Fe3O4 significantly 
inhibited 4T1 and U87 tumor growth in mice. This therapeutic 
effect is attributed to the contribution of a cascade catalytic 
reaction in the tumor tissue.
Another example of a scaffold for cancer therapeutic nano-
reactors is hollow mesoporous organosilica nanoparticles 
(HMONs).[156] Chen and co-workers used HMONs for coen-
capsulation of GOD and l-arginine to achieve cancer starvation 
and gas therapy. In their strategy, GOD oxidizes intratumoral 
glucose to H2O2, which reacts with l-arginine to generate NO, 
which is highly toxic. In vivo experimental results showed that 
systemic injection of HMONs with encapsulated GOD and 
l-arginine into mice bearing U87MG tumors resulted in much 
larger tumor volume suppression than in the cases of GOD-
loaded HMONs and l-arginine-loaded HMONs, indicating a 
synergistic therapeutic effect that is better than that of H2O2 
oxidation monotherapy.
3.2. Glaucoma
Glaucoma is an optic neuropathy that leads to vision loss.[157] 
It has been estimated that glaucoma will affect more than 
80 million individuals worldwide by 2020.[158] The mechanism 
of its progression is not well understood, and intraocular pres-
sure (IOP) is the only proven risk factor. Consequently, reducing 
IOP will arrest the progress of glaucoma. Use of NO, which is 
a signaling molecule, has been successful in lowering IOP, but 
its therapeutic effect strongly depends on the location and con-
centration of NO at the disease site. Stevens and co-workers 
developed a NO delivery platform that can target the conven-
tional outflow pathway (i.e., trabecular meshwork) and produce 
a controlled dose of NO (Figure 15).[159] Their strategy involves 
two steps: the delivery of β-galactosidase-loaded LbL capsules 
to the trabecular meshwork by intracameral injection, followed 
by administration of liposomes loaded with β-galactoside–
NONOate, which is a NO donor prodrug. On degradation of 
the liposomes, β-galactoside–NONOate is released and diffuses 
into the LbL capsules, which results in NO generation. This 
enables dose-dependent production of NO and increases the 
half-life of NO release. A system that made use of these effects 
significantly improved outflow facility in enucleated mice eyes 
compared with that that in the case of treatment with empty 
capsules. This suggests that biocatalytic reactors could be used 
as glaucoma therapeutic materials.
3.3. Neuropathic Pain
Another interesting therapeutic application is neuropathic pain 
treatment with SOD-loaded porous polymer vesicles,[160] which 
was developed by Cheng and co-workers.[161] Neuropathic pain is 
generally caused by injury to the spinal nerve root. A recent study 
showed that neuropathic pain is related to damage to neural tissue 
by ROS.[162] Elimination of ROS may therefore lead to a novel ther-
apeutic approach to neuropathic pain. This goal was achieved by 
loading SOD, which is an antioxidant enzyme, in porous polymer 
vesicles based on PEG-b-poly(butadiene) and PEG–poly(propylene 
glycol)–PEG. The polymer vesicles are permeable, therefore ROS 
can diffuse into the interiors of the polymer vesicles, where they 
are eliminated by interactions with SOD. The withdrawal threshold 
of an ipsilateral injured forepaw after nerve root compression 
was much higher following local administration of SOD-loaded 
polymer vesicles than in the case of free SOD administration. This 
suggests that the treatment can prevent neuropathic pain.
3.4. Alcohol Intoxication
In addition to reactors with single encapsulated enzymes, dual 
enzyme–based nanoreactors for therapeutic application have 
also been reported. Lu and co-workers used enzyme nanocap-
sules, described in Section 2.3.2. They prepared alcohol oxi-
dase (AOx)- and CAT-loaded nanocapsules by DNA-directed 
assembly, followed by in situ polymerization on the enzyme 
surfaces, and demonstrated their therapeutic action as an 
alcohol antidote (Figure 16).[126] Intravenous injection into 
alcohol-intoxicated mice significantly decreased their blood 
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alcohol concentrations (BACs) compared with those of con-
trol groups, including groups treated with AOx nanocapsules, 
CAT nanocapsules, AOx- and CAT-loaded liposomes, and native 
AOx. The BAC reduction was higher than that for mice treated 
with a mixture of AOx and CAT nanocapsules. This indicates 
that the enzyme nanocapsule structure, in which the enzymes 
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Figure 16. A) Schematic diagram of preparation of triple-enzyme nanocapsule by DNA-directed assembly, followed by in situ polymerization on surface 
of enzyme nanocapsules and B) blood alcohol concentrations of ethanol-intoxicated mice treated with PBS, native alcohol oxidase (AOx), AOx nano-
capsules, AOx and CAT nanocapsules, nanocapsules with coencapsulated AOx and CAT, and liposomes with coencapsulated AOx and CAT. Reproduced 
with permission.[126] Copyright 2013, Springer Nature.
Figure 15. A) Schematic diagram of localized delivery of NO to conventional outflow pathway by liposomes containing NO donor (β-galactoside–NON-
Oate) and β-galactosidase-loaded PMA capsules and B) schematic diagram of preparation of β-galactosidase-loaded poly(methacrylic acid) capsules 
formed by layer-by-layer assembly. Reproduced with permission.[159] Copyright 2017, Wiley-VCH.
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are in close proximity to each other, is important. The authors 
concluded that this is probably because of efficient removal of 
H2O2, which might denature the enzymes.
4. Conclusions and Outlook
Therapeutic nanofactories, which are DDSs that enable thera-
peutic enzymatic reactions at disease sites, are becoming recog-
nized as an important tool for biomedical applications. The aim 
of this review was to describe progress in the area of biocatalytic 
reactors and their therapeutic applications. Different kinds of 
compartments such as lipid and polymer vesicles, polymer 
capsules, mesoporous silica particles, viral capsids, and hydro-
gels have been used as scaffolds for biocatalytic reactors. 
Significant achievements from the 1980s to the present have 
been highlighted to introduce these concepts and inspire others 
to use compartments as biocatalytic reactors.
A characteristic of nanofactories is that they can be applied 
to a wide variety of diseases by changing the combination of 
an enzyme and its corresponding substrate. As discussed in 
Section 3, nanofactory-based therapeutics have great potential 
for treating many conditions, including cancer, glaucoma, and 
alcohol intoxication. The rapidly increasing number of papers 
published in this area clearly shows the potential of nanofactory 
use in nanomedicine. However, the use of nanofactories as 
therapeutic agents is far from being a mature field. Many chal-
lenges need to be addressed to enable therapeutic nanofactories 
to be used in vivo, especially in preclinical and clinical trials.
So far, research has focused on the development of com-
partments and investigation of their applicability as enzymatic 
reactors in aqueous solutions or intracellular environments. 
A high encapsulation ability without loss of enzyme activity 
is important for in vitro and in vivo nanofactories. The con-
ventional method for protein encapsulation inside lipid and 
polymer vesicles is film hydration. A lipid or polymer film is 
hydrated with a protein solution, which results in the formation 
of vesicles with encapsulated protein. Although this method is 
facile, the encapsulation efficiency is low (generally less than 
10%)[163–165] and the size of the resultant vesicles is heteroge-
neous. Another method relies on interactions such as electro-
static interactions between the components of the nanofactory 
and enzymes. In this case, high encapsulation efficiency is 
achieved by simply mixing a solution of charged molecules 
with an enzyme solution.[166] However, this method can cause 
denaturation of the enzymes. A more recent method, which 
was reported by Battaglia and co-workers, is based on electropo-
ration.[167] They used electroporation to form transient holes 
in polymer vesicle membranes to enable external proteins to 
enter the vesicles. This method achieved high encapsulation 
efficiencies, notably 17% for BSA and 9% for immunoglob-
ulin G (IgG), without sacrificing protein activity. However, this 
method is only effective for anionic proteins. There is no versa-
tile method for encapsulation of enzymes in compartments and 
suitable methods for encapsulation in individual compartments 
need to be developed.
In addition to the encapsulation efficiency, purification 
methods for compartments with encapsulated enzymes are also 
important because free enzymes can potentially cause side effects 
such as immune responses. Three purification methods are com-
monly used to remove free enzymes: dialysis by ultrafiltration, 
centrifugation, and size-exclusion chromatography (SEC). Dialysis 
is based on the difference between the diffusion rates of enzymes 
and enzyme-encapsulating compartments when passing through 
the pores in dialysis or ultrafiltration membranes. This method 
is simple and cheap. However, the self-assembled compartments 
may decompose during this process because of their dynamic 
equilibrium between unimers and assemblies, which can result 
in a decrease in sample concentration. Centrifugation is also a 
facile separation technique and is based on density differences. 
However, centrifugation can cause aggregation of compartments. 
Currently, the most robust separation method is SEC, which 
separates enzymes and enzyme-encapsulating compartments 
based on their hydrodynamic volumes. SEC columns are typically 
packed with sepharose or sephacryl resin and equipped with a 
UV–vis or refractive index detector. SEC can achieve separation 
and provide information on the amount of encapsulated enzyme. 
SEC is a reliable technique for accurately separating mixtures and 
is an increasingly popular technique.
Another concern for the construction of nanofactory is that 
stability in physiological environments also needs to be taken 
into account in design strategies to ensure that therapeutic 
enzymes are not released before delivery to the disease site. 
The introduction of chemical crosslinking, hydrogen bonding, 
or hydrophobic interactions into compartments may provide 
solutions for this issue. Although the construction of stabi-
lized nanofactories is essential, it is also important for the 
nanofactory compartments to self-destruct when they become 
unnecessary or when controlled termination of treatment is 
necessary. Self-destruction facilitates elimination of nanofactory 
components, including encapsulated enzymes from a living 
body. One potential approach is to use external-stimuli respon-
siveness to tune the compartment stability. Application of an 
external trigger such as light or heat can change the properties 
(e.g., polarity and structure) of stimuli-responsive groups. This 
results in destruction of the compartments. Substantial progress 
has been made in this area, which is not intended for nanofac-
tory construction. Detailed reviews of controlled destruction by 
external stimuli are available in the literature.[168–170]
Considering the benefits of systemic injection, long-term blood 
circulation is another important factor. This can be achieved by 
surface functionalization of the compartments with biocompat-
ible polymers such as PEG[171,172] and poly(amino acids) (e.g., 
polyoxazolines[173] and polysarcosines[174,175]) to reduce elimina-
tion by the mononuclear phagocytic system. Another issue is 
the targeting ability. As discussed in Section 3, all nanofactory 
cancer therapies rely on EPR for accumulation in tumors. Such 
passive targeting in nanomedicine is successful in small animal 
models, but its clinical therapeutic efficacy is limited because of 
the heterogeneity of cancer.[176,177] As an alternative to passive 
targeting based on EPR, active targeting strategies that rely on 
the use of specific ligands (antibodies, peptides, and saccha-
rides) would be advantageous in enhancing accumulation in 
tumors, which would increase the therapeutic efficacy. The func-
tionalization of targeting modules, which is a requirement for a 
nanofactory, has the potential to increase therapeutic versatility.
Recently, the delivery of enzyme-mimetic materials such as 
metal catalysts and artificial enzymes (nanozymes) has attracted 
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attention, not only for chemical labeling of living cells and 
tissues in living bodies,[178–180] but also for activation of thera-
peutics.[181–184] Such nanozymes generally consist of scaffolds 
made of metals, or organic or organic/inorganic hybrid materials 
with embedded metal catalysts. They are stable and can be pro-
duced on a large scale. Additionally, fine-tuning of the chemical 
structures of nanozymes enables catalysis of a wide variety of reac-
tions, therefore nanozymes are promising and valuable materials. 
However, their encapsulation in stable scaffolds would make them 
more effective for in vivo applications. The manipulation of metal 
catalysts encapsulated in permeable compartments, as described 
in this review, will therefore be an important future direction for 
therapeutic nanofactories. Furthermore, combinations of natural 
enzymes and metal catalyst might enable the development of 
highly effective and safe therapeutics for clinical applications.
Overall, we have no doubt that research in the field of bio-
catalytic reactors, which has matured dramatically in the last 
5 years, will continue to focus on the development of in vivo 
therapeutic nanofactories in the next few years. This new class 
of therapeutics holds great promise for the treatment of various 
diseases, and their applicability not only in therapeutics but 
also for sensing and diagnosis will expand. It is expected that 
a range of scientific communities, from chemists to medical 
researchers, will be involved in tackling the many challenges 
in this field and will enable the development of new preclinical 
and clinical applications in the near future.
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